MTOR and Cowden disease: Another subset of NET patients are genetically predisposed to mammalian/mechanistic target of rapamycin (mTOR) pathway dysregulation, due to suffering from tuberous sclerosis complex (affecting TSC1, TSC2) [42] or Cowden syndrome (affecting PTEN) [43].